Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Cerebral Venous Thrombosis in Patients with COVID-19 Infection: a Case Series and Systematic Review

Tian Ming Tu, MBBS,* Claire Goh, MBBS,† Ying Kiat Tan, MBBS,† Aloysius ST Leow, MBBS,‡ Yu Zhi Pang, MBBS,* Jaime Chien, MBBS,* Humaira Shafi, MBBS,* Bernard PL Chan, MB ChB,‡ Andrew Hui, MBBS,§ Jasmine Koh, MBBS,* Benjamin YQ Tan, MBBS,†‡ N. Thirugnanam Umapathi, MBBS,* and Leonard LL Yeo, MBBS†‡

Background: There has been increasing reports associating the coronavirus disease 2019 (COVID-19) with thromboembolic phenomenon including ischemic strokes and venous thromboembolism. Cerebral venous thrombosis (CVT) is a rare neurovascular emergency that has been observed in some COVID-19 patients, yet much remains to be learnt of its underlying pathophysiology. Objective: We present a case series of local patients with concomitant COVID-19 infection and CVT; and aim to perform a systematic review of known cases in the current literature. Methods: We describe two patients with concomitant COVID-19 infection and CVT from a nationwide registry in Singapore. We then conducted a literature search in PubMed and Embase using a suitable keyword search strategy from 1st December 2019 to 11th June 2020. All studies reporting CVT in COVID-19 patients were included. Results: Nine studies and 14 COVID-19 patients with CVT were studied. The median age was 43 years (IQR=36-58) and majority had no significant past medical conditions (60.0%). The time taken from onset of COVID-19 symptoms to CVT diagnosis was a median of 7 days (IQR=6-14). CVT was commonly seen in the transverse (75.0%) and sigmoid sinus (50.0%); 33.3% had involvement of the deep venous sinus system. A significant proportion of patients had raised D-dimer (75.0%) and CRP levels (50.0%). Two patients reported presence of antiphospholipid antibodies. Most patients received anticoagulation (91.7%) while overall mortality rate was 45.5%. Conclusions: The high mortality rate of CVT in COVID-19 infection warrants a high index of suspicion from physicians, and early treatment with anticoagulation should be initiated.

Key Words: Anticoagulation—Cerebral venous thrombosis—Coronavirus disease 2019—Mortality—Systematic review

© 2020 Elsevier Inc. All rights reserved.

Introduction

Cerebral venous thrombosis (CVT) is a rare neurovascular emergency, and its incidence is estimated to be around 1.6 cases per 100,000 per year in a population-based study.1 While the occurrence of arterial acute ischemic stroke (AIS) as a devastating neurologic complication is increasingly being reported on, there have been sporadic case reports and case series examining the association between CVT and coronavirus disease 2019 (COVID-19) infection.2 Several studies have illustrated a higher preponderance to venous thromboembolic manifestations, such as deep vein thrombosis and pulmonary
embolism, especially in the critically ill cohorts. However, the true incidence of cerebral venous thrombosis occurrence in COVID-19 patients remains unknown. Furthermore, the underlying mechanism of CVT in COVID-19 patients remains debatable. It has been proposed that COVID-19 may induce a prothrombotic state, as supported by the elevated levels of factor VIII, fibrinogen, D-dimer and circulating prothrombotic microparticles such as antiphospholipid antibodies.

Given the rapidly rising number of COVID-19 infections globally and the severity of CVT as a complication, it is critical to derive a more in-depth understanding of their association, clinical manifestations, severity and treatment outcomes.

In this report, we present a case series of patients with concomitant COVID-19 infection and CVT from Singapore. We subsequently perform a systematic review of the current literature to evaluate patient demographics, clinical characteristics, prothrombotic workup, neuroimaging findings, treatment and outcomes of COVID-19 patients who have suffered CVT.

**Methods**

**Local case series and incidence**

We identified 3 patients with concomitant COVID-19 infection and CVT from a nationwide registry capturing cases of neurological manifestations in COVID-19 from all public healthcare institutions in Singapore. In 1 patient, CVT was found after significant trauma and was excluded from this case series and analyses (Fig. 1). The total number of COVID-19 infections at the time of reporting was obtained from the Ministry of Health, Singapore. Incidence was calculated as the proportion of patients with CVT amongst all COVID-19 cases. We describe the remaining 2 cases and include details on their clinical presentation, prothrombotic workup, neuroimaging findings, treatment and outcomes. Ethics approval was obtained from the Singapore Health Services (CIRB 2020/2410) institutional review board.

**Methods of systematic review**

**Literature search strategy**

We conducted the systematic review in accordance with the PRISMA guidelines. A comprehensive literature search was performed on PubMed and Embase from 1st December 2019, before the first case of COVID-19 was reported, to 11th June 2020. The search strategy consisted of different combinations of the following search terms: COVID, Coronavirus, Severe acute respiratory syndrome coronavirus 2, CoV, SARS-CoV-2, cerebral vein thrombosis, cerebral venous thrombosis, cerebro-venous thrombosis, cerebrovenous thrombosis, cerebral sinus thrombosis, cerebral sinus venous thrombosis, cerebral sinovenous thrombosis, venous sinus thrombosis, sinus thrombosis, sinovenous thrombosis, CVT, cavernous sinus thrombosis, lateral sinus thrombosis, superior sinus thrombosis, cortical sinus thrombosis, cortical venous thrombosis, cortical vein thrombosis, dural sinus thrombosis, dural venous thrombosis, dural vein thrombosis, deep cerebral vein thrombosis, deep cerebral venous thrombosis, deep cerebral thrombosis, intracranial sinus thrombosis, intracranial venous thrombosis, intracranial vein thrombosis, thrombus, clot, prothrombotic and coagulopathy. The search was performed by two independent reviewers (YKT & CG). During study screening for relevance, any disagreement was resolved by consensus with the senior author (LY). The reference lists of these articles were also screened, and hand searched to identify further relevant studies.

**Study and cohort selection**

All studies (case reports, case series and observational cohort studies) that reported cerebral venous thrombosis in COVID-19 patients were included during the initial search. We subsequently excluded all studies that reported only acute ischemic stroke, hemorrhagic stroke and those without an English translation.

**Data extraction**

Relevant quantitative data were extracted by two authors (YKT & CG) in the form of absolute frequencies of events or absolute numbers when appropriate. Where available, the data included incidence rate, individual case data: patient demographics (age, gender), country of study origin, comorbidities, COVID-19 symptoms, duration of neurologic deficit from symptom onset, National Institutes of Health Stroke Scale (NIHSS), location of thrombosis, relevant laboratory results (white cell count, absolute lymphocyte count, platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), c-reactive protein (CRP), D-dimer, fibrinogen, lactate dehydrogenase (LDH), and ferritin), treatment (anticoagulation, endovascular treatment, or neurosurgery) and inpatient mortality. Neuroimaging data reported in text or image format was reviewed by two neurologists (TTM & LY).

**Risk of bias assessment**

The quality of the included case reports and case series was assessed using the guidelines recommended by the Jhonna Briggs Institute. For case series, each study was assessed if there were clear inclusion criteria, measured the condition in a reliable way, had a valid method to identify condition, had consecutive or complete inclusion and reported patient demographics, clinical information, and outcomes. For case reports, each study was assessed if the following was well described: patient demographics,
medical history, clinical conditions, diagnostic tests, treatment, post-treatment clinical condition, adverse events and takeaway lessons.

**Statistical analyses**

All data analysis was conducted using IBM SPSS Statistics 25.0 software. Individual case data were pooled with patient demographics, COVID-19 symptoms, stroke characteristics, treatment and clinical outcomes.

**Results**

**Local case series and incidence**

As of 3 July 2020, Singapore had reported 44,479 confirmed COVID-19 cases. Of these COVID-19 cases, we describe 2 patients with concomitant CVT and COVID-19 infection, deriving an incidence of 2/44,479 (0.0045%) or 4.5 per 100,000 COVID-19 cases.

Case 1:
A mid-thirties man with no past medical history of note and a non-smoker, presented with pleuritic left sided chest pain of 4 days duration. He also complained of fever and chills of 1-day duration. He visited his general practitioner and was subsequently referred to the emergency department. He was living in a dormitory with COVID-19 positive patients. Clinical examination at the emergency department was unremarkable and a chest radiograph was normal. Despite his lack of physical findings, the nasal and pharyngeal swabs were positive for COVID-19 via RT-PCR test. Other laboratory results, including the full blood count, C-reactive protein, D-dimer levels, and anticardiolipin IgG were within normal limits (Fig. 1).

The patient started to develop a generalized non-remitting headache on the day of presentation, which did not improve with analgesia. Magnetic resonance imaging (MRI) of the brain with contrast and magnetic resonance venogram (MRV) was performed which demonstrated a left transverse and sigmoid sinus thrombosis (Fig. 2). No abnormal susceptibility signal to denote an intracranial hemorrhage was noted on the GRE sequence. Lumbar puncture was performed to exclude meningitis in view of the presence of headache and fever. Cerebrospinal fluid (CSF) analysis demonstrated 3 nucleated cells per mm$^3$ (normal 0-5 cells/mm$^3$), 1000 red blood cells per mm$^3$ (normal 0-5 cells/mm$^3$) and raised protein at 0.76 g/L (normal 0.1-0.4g/L). CSF was negative for COVID-19 on RT-PCR test. The patient was initiated with dabigatran for the treatment of his cerebral venous thrombosis. He was discharged well. A follow up repeat CT venogram was
performed four weeks after the initial MRV which demonstrated complete resolution of the venous thrombosis.

Case 2:
A man in his late thirties with no significant past medical history presented with a first-onset seizure. He stayed in the dormitory and was witnessed to have a generalized tonic-clonic convulsion that lasted around 5 min by his friends. During this episode, he fell and struck the back of his head on the floor. An ambulance transferred him to the emergency department where he was found to be confused and restless, with a GCS of 13. Clinical examination revealed a right parietal scalp hematoma, but no fever or any abnormal respiratory findings. The chest radiograph was normal. An urgent CT brain and CT venogram revealed a thrombosis in the left transverse and sigmoid sinuses, extending into the left internal jugular vein, as well as an acute left temporal lobe intraparenchymal hematoma (Fig. 3). Laboratory tests showed raised D-dimer (4.6 mg/L), CRP (7.3 mg), elevated homocysteine levels (119.2 umol/L, normal values 5.0 - 15.0 umol/L), presence of lupus anticoagulant and low protein C activity (53%, normal 83-144%). Anticardiolipin and anti-B2-glycoprotein I IgG and IgM were within normal limits. In view of the outbreak situation in the Singapore dormitories, COVID-19 screening was performed, where nasal and pharyngeal swabs were positive for the reverse transcriptase-polymerase chain reaction (RT-PCR) test. Given the extensive cerebral venous thrombosis, the patient was initiated on anticoagulation with IV heparin, in addition to IV levetiracetam for seizures and cobalamin replacement. A week into his admission, the patient deteriorated neurologically. Urgent CT brain demonstrated increased size of hemorrhage and edema with mid-line shift, and decompressive craniectomy was performed emergently. Despite surgical intervention, he passed away the following day.

Systematic review results
The electronic search strategy yielded 819 studies, with one additional study found after screening through reference lists. After removing duplicates, 543 records were screened based on abstracts, of which a further 499 studies were excluded as they reported only acute ischemic stroke, hemorrhagic stroke or did not have an English translation. Lastly, 35 articles were excluded after full-text review (reported only on coagulopathy (n=13), venous thromboembolism events unrelated to CVT (n=11), were editorials/opinion letters to editors (n=5), were reviews (n=2), reported only on acute ischemic stroke (n=2), pulmonary embolism (n=1), cardiopulmonary complications (n=1)). Overall, nine studies with 12 patients from the existing literature were included in this systematic review. The study selection process is shown in the PRISMA flowchart (Fig. 4)8-16, while Supplementary Table 1 presents the grading of the studies. Adding 2 patients from our current local case series, we included a total of 14 patients with COVID-19 infection and CVT for descriptive analyses.

The clinical characteristics of the 14 patients were shown in Table 1. The majority of the patients were middle-aged (median 43 years, IQR=36-58 years) and male (64.3%). Most patients had no significant past medical conditions prior to the CVT episode (57.1%). Symptoms related to COVID-19 infection were commonly observed in these patients including fever (75.0%), acute respiratory infection (ARI) symptoms (50.0%), and dyspnea (41.7%). Two patients (14.3%) did not display any symptoms related to COVID-19 infection. CVT was observed in patients across a spectrum of COVID-19 disease severity, with 35.7% having mild infection, 28.6% of moderate severity and 35.7% with severe or critical illness. In addition, patients with CVT displayed a range of neurological symptoms.
symptoms attributed to the CVT such as altered mental status (38.5%), headache (30.8%), hemiparesis (30.8%), and reduced consciousness level (30.8%). The time taken from onset of COVID-19 symptoms to diagnosis of CVT was a median of 7 days (IQR=6-14 days).

Presence of CVT in the transverse sinus (75.0%) and sigmoid sinus (50.0%) was seen in the majority of the cases (Figure 1). Involvement of the deep venous sinus system was also commonly observed, with 33.3% having internal cerebral vein or straight sinus thrombosis. Intracranial bleeding was seen on initial neuroimaging in 61.5% of patients.

In terms of laboratory findings, a significant proportion of patients had raised D-dimer (75.0%) and CRP levels (50.0%). Antibody testing was reported in four patients. Patient 4 had raised anti-cardiolipin IgM, while Patient 14 had positive lupus anticoagulant but normal anti-cardiolipin and anti-B2-glycoprotein-I IgM and IgG titers. In contrast, Patient 5 had normal anti-cardiolipin, anti-B2-glycoprotein-I and anti-dsDNA IgM titers while Patient 13 had normal anti-cardiolipin IgM and IgG titers.

In the 12 patients with information provided on CVT treatment, most received anticoagulation (91.7%). Of note, Patient 1 underwent percutaneous venous mechanical thrombectomy with adjunct catheter-directed thrombolysis, while Patient 2 had an external ventricular drain inserted due to interval development of venous infarction with hemorrhagic transformation, intraventricular hemorrhage, and obstructive hydrocephalus. Overall, mortality rate reported amongst COVID-19 patients with CVT in this study was 45.5%, while mortality rate amongst the subgroup of mild COVID-19 patients was 40.0%.

Discussion

This systematic review highlights the occurrence of CVT in patients across the spectrum of severity of COVID-19 infection. Of note, the majority of these patients were middle-aged and without significant comorbidities. The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first recognized in Wuhan after a cluster of atypical pneumonia was reported. Since then, the pandemic has grown rapidly and reached global proportions, overwhelming healthcare systems around the world. Being a novel coronavirus, much is to be learnt about its various clinical manifestations. Interestingly, multiple studies have reported neurological manifestations of the COVID-19 infection, whereby 36.4% of patients were found to have neurological symptoms and that those with severe infection were further associated with strokes and coagulopathy. Indeed, new evidence seems to suggest a tendency for severe COVID-19 infection to trigger cytokine storms which leads to a proinflammatory and prothrombotic state. These patients may thus suffer from thromboembolic events, both arterial and venous. However, it is surprising that in this systematic review of patients with concomitant COVID-19 and CVT, a large majority were relatively young and
**Table 1. COVID-19 patients with cerebral venous thrombosis.**

| Study | Patient Country | Age (years) | Sex | Co-morbidities | COVID-19 symptoms | COVID-19 severity* | Neurological symptoms | Days from COVID-19 symptoms | Location of CVT | Prothrombotic work-up | Treatment | Outcome |
|-------|-----------------|-------------|-----|----------------|-------------------|-------------------|---------------------|--------------------------|-----------------|------------------------|------------|---------|
| Cavalcanti 1 | US | 38 | M | Mild ASD | Diarrhea, vomiting, Fever, Headache | Critical | AMS | 10 | Cortical veins, R internal cerebral vein, straight sinus, distal superior sagittal sinus, torcular and R transverse sinus | Nil | EVT ACC | Death |
| 2 | 41 | F | Nil | | Mild | AMS Aphasia | | | Vein of Galen, internal cerebral veins, distal straight sinus | Yes | Raised D-dimer | EVD ACC | Death |
| 3 | 23 | M | Nil | ARI, fever Headache | Lethargy | Critical | GCS drop | 7 | Distal L transverse and sigmoid sinus | Yes | Raised D-dimer, ferritin | Nil | Death |
| Klein 4 | US | 29 | F | Nil | ARI, dyspnea, fever Headache | Mild | Post-ictal AMS Aphasia | >7 | Vein of Galen, L internal cerebral vein, straight sinus | Nil | Raised D-dimer, Normal anti-CL, anti-B2gp1 IgM | ACC | Alive |
| Garaci 5 | Italy | 44 | F | Nil | ARI, dyspnea, fever | Severe | Facial palsy Seizure | 14 | Vein of Galen, L internal cerebral vein, straight sinus | Nil | Raised CRP, D-dimer, LDH, anti-CL IgM Low ferritin | ACC | Death |
| Malentacchi 6 | Italy | 81 | M | Prostate CA CLL | Dyspnea | Critical | AMS GCS drop | 7 | R sigmoid sinus | Nil | Raised CRP, D-dimer, anti-dsDNA IgM | ACC | Death |
| Hughes 7 | UK | 59 | M | Obesity HTN DM | Fever Headache | Moderate** | Aphasia Dysarthria R hemiparesis R hypoesthesia | 4 | R transverse and sigmoid sinuses | Nil | Raised fibrinogen, CRP, ESR | ACC | Discharged |
| Dahl-Cruz 8 | Spain | 53 | M | Nil | Anosmia, dysgeusia ARI, dyspnea, fever Headache | Moderate** | Ataxia R hemiparesis R hypoesthesia | 7 | Superior sagittal and R transverse sinus | Yes | Raised CRP, D-dimer | ACC AED Discharged |
| Poillon 9 | France | 62 | F | Obesity | ARI, dyspnea, fever Headache | Moderate | Blurry vision GCS drop Headache R hemiparesis | 15 | Vein of Galen, internal cerebral vein, straight sinus, L transverse sinus | Yes | Raised D-dimer | | |
| 10 | 54 | F | Breast CA | ARI, fever Lethargy | Moderate | Headache | 14 | R transverse sinus | Yes | Raised CRP, D-dimer Normal LDH | ACC AED Discharged |
| Hemasian 11 | Iran | 65 | M | Nil | ARI, dyspnea, Fever Headache | Mild | GCS drop Seizure | 15 | R transverse and sigmoid sinuses | Yes | Raised LDH Normal CRP, ESR | ACC AED Discharged |
| Li 12 | China | 32 | M | Smoking | | Severe | | | | Normal CRP, D-dimer, anti-CL IgM and IgG | ACC | Alive |
| Tu 13 | SG | 30s | M | Nil | Fever | Mild | Headache | 1 | R transverse and sigmoid sinuses | Nil | Raised CRP, D-dimer, homocysteine, LAC, low protein C activity Normal protein S, anti-CL, anti-B2gp1 IgM and IgG | ACC AED Discharged |

Abbreviations: ACC – anticoagulation; AED – anti-epileptic drug; AMS – altered mental status; ARI – acute respiratory infection symptoms; ASD – autism spectrum disorder; CA – cancer; COVID-19 – coronavirus disease 2019; CVT – cerebral venous thrombosis; DM – diabetes mellitus; EVD – external ventricular drain; EVT – endovascular thrombectomy; F – female; GCS – Glasgow coma scale; ICH – intracranial hemorrhage; LAC – lupus anticoagulant; M – male; US – United States; UK – United Kingdom

ARI includes sore throat, rhinorrhea, blocked nose, cough, myalgia; Prothrombotic work-up includes CRP, D-dimer, ESR, ferritin, fibrinogen, LDH, anti-dsDNA / antiphospholipid antibodies where available

*Severity according to “Clinical management of COVID-19” Interim guidance 27/5/2020 from WHO

**Moderate but has bilateral infiltrates on CXR/CT thorax
healthy patients with relatively few co-morbidities. In addition, a significant proportion of CVT patients only displayed mild to moderate severity of COVID-19 infection, thus indicating that a hypercoagulable state may be present even in mild infection.

We propose that the presence of COVID-19 should be screened in patients presenting with neurological complications CVT without prominent respiratory symptoms nor known prothrombotic risk factors. From our systematic review, four (28.6%) patients (case 2, 11, 13 and 14) presented initially with neurological symptoms and all had no prothrombotic risk factors. Moreover, COVID-19 could have been potentially missed as all 4 had mild respiratory symptoms. For our local 2 cases (13, 14), COVID-19 was only diagnosed due to pro-active testing with RT-PCR, as they were living in workers dormitories where other cases of COVID-19 were known to occur. Additionally, the incidence of CVT in COVID-19 appears to be approximately 3 times higher than previously published population incidence (4.5 per 100,000 vs 1.6 per 100,000).

The presence of concomitant COVID-19 infection and CVT seems to portend a much poorer prognosis than each condition individually. This study found an unusually high mortality rate of 45.5% in COVID-19 patients diagnosed with CVT, in contrast to the known mortality rates of CVT at 15% and current estimates of COVID-19 case fatality rate of 5.6%.22 One possibility for the poorer outcome in these patients may be due to the location of the occluded sinuses, which showed a higher predilection for the deep venous sinuses to be involved. Thrombus in the internal cerebral veins or straight sinus was seen in 33.3% of the patients and these sites of thrombosis are typically rare and have a higher morbidity and mortality rate.24 Consequently, this may be a contributing factor to the high mortality reported in our series, where 50% of the patients who died had involvement of the deep cerebral veins.

Many studies in the current COVID-19 literature have reported cases of arterial and venous thromboembolism, attributed to deranged coagulopathy, extensive systemic inflammation and endothelial dysfunction that are associated with severe COVID-19 [25]. The incidence of venous thromboembolism reported thus far has ranged from 4.4% to 19.7%, with a remarkably high rate seen in the subgroup of severe COVID-19 patients in ICU reaching up to 69%.4, 26, 27 This has led to several recommendations being made for the use of anticoagulation in hospitalised COVID-19 patients, where those treated with anticoagulation were observed to have improved outcomes.19, 28 At the same time, anticoagulation with low molecular weight or unfractionated heparin remains the mainstay of treatment in CVT.29 Given the higher mortality rates of CVT seen in COVID-19 infection, there may be a role for early initiation of anticoagulation in patients suspected to have CVT or predisposed to its formation. Amongst the patients treated with anticoagulation, 60.0% survived which is an encouraging sign. Lastly, thrombectomy is a therapeutic option in patients with severe CVT, not unlike those with concomitant COVID-19.24 In this study, while the only patient (case 1) who underwent endovascular treatment died, this may be related to the need for a salvage endovascular maneuver in a deteriorating patient despite anticoagulation rather than a reflection of the inability of endovascular treatment in COVID-19 patients with CVT.

Limitations
The following limitations of this study should be acknowledged. Firstly, the patients included in this study were from case reports and case series which are retrospective in nature and may be limited by data availability or accuracy. Secondly, the number of COVID-19 patients with CVT included in the analysis is small (n=14), which did not allow for further comparative analysis. The actual number of COVID-19 patients with CVT may be significantly higher but not detected as clinical suspicion may be low in a large number of COVID-19 patients who are intubated and without appropriate imaging done. Thirdly, there was insufficient data available from published studies to evaluate the overall incidence of CVT. However, we were able to calculate the local incidence of CVT in COVID-19 patients (4.5 per 100,000), which is higher than the previously published incidence of 1.6 per 100,000 in other population-based studies.1 Lastly, while the aforementioned factors limit the generalizability of the results, it is nevertheless useful in highlighting a likely association between COVID-19 infection and CVT, serving as a basis for future large cohort studies.

Conclusion
Whilst infrequently reported, CVT has been found to occur in patients with COVID-19 infection. The unusually high mortality rate warrants a high index of suspicion from physicians, and early treatment with anticoagulation should be initiated in these settings.

Declaration of Competing Interest
There are no conflict of interests.

Funding
None

Availability of data and material
All data relevant to the study are included in the article or uploaded as supplementary information.

Patient consent for publication
Waiver of consent was granted by the Singapore Health Services institutional review board as the data collected was
based on routine clinical care and in view of the nature of the pandemic.

Acknowledgements

None

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.jstrokecerebrovasdis.2020.105379.

References

1. Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study. Stroke 2016;47(9):2180-2182.

2. Beyrouti R, Adams ME, Benjamín L, Cohen H, Farmer SF, Goh YY, Humphries F, Jäger HR, Losseff NA, Perry RJ, Shah S. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry 2020.

3. Klok FA, Kruijff MJ, Van Der Meer NJ, Arbous MS, Heijmans J, Smits LP, Bonta PI, van Es N. Incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thrombosis Res 2020.

4. Lodigiani C, Iapichino G, Carenzo L, Ferrazzi P, Sebastian T, Kucher N, Studt JD, Sacco C, Alexia B, Lillemoe K, Nossek E, Torres J, Jain R, Riina HA, Radakers M, Auvray M, Merouani K. High incidence of venous thromboembolic events in anticoagulated severe coronavirus disease 2019 patients admitted to an academic hospital in Milan. Italy. Thrombosis Res 2020.

5. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembero C, Chantarangkul V, Tripodi A. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A report of thromboelastography findings and other parameters of hemostasis. J Thrombosis Haemostasis 2020. https://doi.org/10.1111/jth.14850.

6. Valderrama EV, Humbert K, Lord A, Frontera J, Yaghi S. Severe acute respiratory syndrome 2 infection and ischemic stroke. Stroke 2020. https://doi.org/10.1161/strokeaha.120.030153.

7. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Zhang S. (2020). Coagulopathy and antiphospholipid antibodies in patients with Covid-19. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161262/.

8. Cavalcanti DD, Raz E, Shapiro M, Dehkargarhi S, Yaghi S, Lillemoe K, Nokseb E, Torres J, Jain R, Kimba A, Radmanesh A, Nelson PK. Cerebral venous thrombosis associated with COVID-19. Am J Neuroradiol 2020. https://doi.org/10.3174/ajnr.A6644.

9. Dahl-Cruz F, Guevara-Dalrymple N, López-Hernández N. [Cerebral venous thrombosis and SARS-CoV-2 infection]. Rev Neurol 2020;70(10):391-392. https://doi.org/10.33588/rn.7010.202004.

10. Garaci F, Di Giuli ano F, Picchi E, Da Ros V, Floris R. Venous cerebral thrombosis in COVID-19 patient. J Neurol Sci 2020;414:116871. https://doi.org/10.1016/j.jns.2020.116871.

11. Hemasian H, Ansari B. First case of Covid-19 presented with cerebral venous thrombosis: a rare and dreaded case. Rev Neurol (Paris) 2020. https://doi.org/10.1016/j.neurol.2020.04.013.

12. Hughes C, Nichols T, Pike M, Subbe C, Elghenzai S. Cerebral venous sinus thrombosis as a presentation of COVID-19. Eur J Case Rep Intern Med 2020;7(5):001691. https://doi.org/10.12890/2020_001691.

13. Klein DE, Libman B, Kisch C, Arora R. Cerebral venous thrombosis: atypical presentation of COVID-19 in the Young. J Stroke Cerebrovasc Dis 2020:104989. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104989.

14. Li Y, Wang M, Zhou Y, Chang J, Xian Y, Mao L, Hu B. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. SSRN Electron J 2020. https://doi.org/10.2139/ssrn.3550025.

15. Malentacchi M, Gied D, Angelino V, Demichelis S, Perboni A, Veltri A, Bertolotto A, Capobianco M. Concomitant brain arterial and venous thrombosis in a COVID-19 patient. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14380.

16. Poillon G, Obadia M, Perrin M, Savatovsky J, Lecler A. Cerebral venous thrombosis associated with COVID-19 infection: causality or coincidence? J Neuroradiol = J De Neuroradiologie 2020. https://doi.org/10.1016/j.neurad.2020.05.003.

17. Timeline of who’s response to COVID-19. WHO | World Health Organization; 2020. https://www.who.int/news-room/detail/29-06-2020-covidtimeline.

18. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Hu B. Neurolgic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. China. JAMA Neurology 2020. https://doi.org/10.1001/jamaneurol.2020.1127.

19. Connons JM, & Levy JH. (2020). Thromboinflammation and the hypercoagulability of COVID-19. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/32302453.

20. Tang N, Bai H, Chen X, Gong J, Li D, & Sun Z. (2020, April 27). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Retrieved from: https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14817.

21. Tan YK, Goh C, Leow AS, Tambyah PA, Ang A, Yap ES, Tu TM, Sharma VK, Yeo LL, Chan BP, Tan BY. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thrombosis Thrombolysis 2020;1-9. https://www.ncbi.nlm.nih.gov/pubmed/32302453.

22. Baud D, Qi X, Nielsen-Saines K, Musso D, Pormar L, Favre G. Real estimates of mortality following COVID-19 infection. The Lancet. Infectious Dis 2020;20(7):773 10.1016/S1473-3099(20)30195-X.

23. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. The Lancet. Neurology 2007;6(2):162-170. 10.1016/S1474-4202(07)70029-7.

24. Yeo LL, Lye PP, Yee KW, Cunli Y, Ming TT, Ho AF, Tu TM, Sharma VK, Yeo LL, Chan BP, Tan BY. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thrombosis Thrombolysis 2020;1-9. https://doi.org/10.1007/s11239-020-02228-y.

25. Hess DC, Eldashah W, Rutkowski E. COVID-19-related stroke. Transl Stroke Res 2020;11(3):322-325. 10.1007/s12975-020-00816-9.

26. Midddelborg S, Coppenes M, van Haaps TF, Foppen M, Vlaar AP, Müller M, Bouman C, Beenen L, Koette RS, Heijmans J, Smits LP, Bonta PI, van Es N. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thrombosis Haemostasis: JTH 2020. https://doi.org/10.1111/jth.14888. Advance online publication 10.1111/jth.14888.

27. Litjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K. High incidence of venous thromboembolic events in anticoagulated severe
COVID-19 patients. J Thrombosis Haemostasis: JTH 2020;18(7):1743-1746. 10.1111/jth.14869.
28. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, Zhao S, Nadkarni GN. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am College Cardiol 2020;76(1):122-124 10.1016/j.jacc.2020.05.001.
29. Ferro JM, Canhão P. Cerebral venous sinus thrombosis: update on diagnosis and management. Current Cardiol Rep 2014;16(9):523. 10.1007/s11886-014-0523-2.